132 related articles for article (PubMed ID: 33441299)
1. Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.
van Mulligen E; van der Helm-van Mil A; de Jong PHP
Ann Rheum Dis; 2023 Oct; 82(10):e217. PubMed ID: 33441299
[No Abstract] [Full Text] [Related]
2. Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive.
Greenwood M; Shipa M; Yeoh SA; Roussou E; Mukerjee D; Ehrenstein MR
Ann Rheum Dis; 2020 Nov; 79(11):1516-1517. PubMed ID: 32467248
[No Abstract] [Full Text] [Related]
3. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
[TBL] [Abstract][Full Text] [Related]
4. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.
Teitsma XM; Devenport J; Jacobs JWG; Pethö-Schramm A; Borm MEA; Budde P; Bijlsma JWJ; Lafeber FPJG
PLoS One; 2020; 15(12):e0241189. PubMed ID: 33301475
[TBL] [Abstract][Full Text] [Related]
7. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
Naniwa T; Iwagaitsu S; Kajiura M
Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481
[No Abstract] [Full Text] [Related]
8. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
9. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.
de Moel EC; Derksen VFAM; Stoeken G; Trouw LA; Bang H; Goekoop RJ; Speyer I; Huizinga TWJ; Allaart CF; Toes REM; van der Woude D
Arthritis Res Ther; 2018 Feb; 20(1):33. PubMed ID: 29482627
[TBL] [Abstract][Full Text] [Related]
10. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.
de Moel EC; Derksen VFAM; Trouw LA; Bang H; Collée G; Lard LR; Ramiro S; Huizinga TWJ; Allaart CF; Toes REM; van der Woude D
Arthritis Res Ther; 2019 Jan; 21(1):28. PubMed ID: 30658699
[TBL] [Abstract][Full Text] [Related]
11. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
Alessandri C; Bombardieri M; Papa N; Cinquini M; Magrini L; Tincani A; Valesini G
Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
[TBL] [Abstract][Full Text] [Related]
12. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
Zhou M; Xu R; Kaelber DC; Gurney ME
PLoS One; 2020; 15(3):e0229819. PubMed ID: 32203525
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.
Gulácsi L; Zrubka Z; Brodszky V; Rencz F; Alten R; Szekanecz Z; Péntek M
Adv Ther; 2019 Mar; 36(3):721-745. PubMed ID: 30637590
[TBL] [Abstract][Full Text] [Related]
14. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort).
Duquenne C; Wendling D; Sibilia J; Job-Deslandre C; Guillevin L; Benichou J; Flipo RM; Guillemin F; Saraux A
Clin Exp Rheumatol; 2017; 35(4):638-646. PubMed ID: 28516872
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody-mediated bone loss.
Harre U; Kittan NA; Schett G
Curr Osteoporos Rep; 2014 Mar; 12(1):17-21. PubMed ID: 24407713
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.
Fautrel B; Belhassen M; Hudry C; Woronoff-Lemsi MC; Levy-Bachelot L; Van Ganse E; Tubach F
Joint Bone Spine; 2020 May; 87(3):267-269. PubMed ID: 31606495
[No Abstract] [Full Text] [Related]
19. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients.
Ling SF; Nair N; Verstappen SMM; Barton A; Zucht HD; Budde P; Schulz-Knappe P; ; Plant D
Pharmacogenomics J; 2020 Jun; 20(3):516-523. PubMed ID: 31819160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
